SCHEMBL6404601

SCHEMBL6404601

CC(CCNC(=O)O)CC(=O)N(CCCc1ccccc1)CS(=O)(=O)Nc1cccc(C(C)O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.46
NAMPT P43490 1/20 0.36
PKM P14618 1/20 0.35
EPHX2 P34913 2/20 0.35
KMT2A Q03164 5/20 0.35
MEN1 O00255 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ADRB3 P13945 1/20 0.34
OPRM1 P35372 2/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
PTGES O14684 1/20 0.34
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
ADRB2 P07550 1/20 0.33
OPRL1 P41146 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6401746 0.90 LMNA (0.42) LMNA
SCHEMBL6403803 0.88 KMT2A (0.45) LMNAPKMKMT2AMEN1NPC1
SCHEMBL6403042 0.79 HTT (0.41) LMNAKMT2AMEN1RAB9AALDH1A1
SCHEMBL6404595 0.78 LMNA (0.48) LMNANAMPTEPHX2KMT2AMEN1
SCHEMBL7253042 0.77 PTGES (0.42) PTGES
SCHEMBL6409458 0.77 NPC1 (0.42) LMNANAMPTKMT2ANPC1RAB9A
SCHEMBL6401980 0.75 LMNA (0.45) LMNANAMPTKMT2AMEN1KDM4E
SCHEMBL7253037 0.75 LMNA (0.46) LMNANAMPTKMT2AMEN1KDM4E
SCHEMBL6405210 0.74 NPC1 (0.43) LMNANAMPTNPC1RAB9ASMN1; SMN2
SCHEMBL6401317 0.73 NPC1 (0.47) LMNANAMPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900237-B2 Sulfonamide compounds as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-05-31 US claimed
US-20030158231-A1 Sulfonamide compounds as protease inhibitors Celera Corporation 2003-08-21 US claimed
US-6900237-B2 Sulfonamide compounds as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-05-31 US disclosed
US-20030158231-A1 Sulfonamide compounds as protease inhibitors Celera Corporation 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158231-A1 Sulfonamide compounds as protease inhibitors PRSS1, PRSS3, SPINT2 LMNA 3804/4885NAMPT 375/4885PKM 4037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.